Aanesthetic Agents for Day Surgery - NIHR Health Technology ...

Contents
Appendix 6 Adult patient-based
outcomes studies............................................ 147
Appendix 7 Paediatric patient-based
outcomes studies............................................ 159
Appendix 8 Characteristics of cost or
economic comparisons of anaesthetic
agents.............................................................. 163
Appendix 9 Quality of cost or economic
comparisons of anaesthetic agents .............. 165
Appendix 10 Studies excluded from the
literature review ............................................ 175
Appendix 11 National survey of
anaesthetic practice ...................................... 181
Appendix 12 The scientific advisory
group .............................................................. 189
Appendix 13 Development of the
contingent valuation tool .............................. 191
Appendix 14 Contingent valuation
scenario for induction of anaesthesia .......... 195
Appendix 15 Contingent valuation
scenario for maintenance of anaesthesia .... 197
Appendix 16 Patients’ views, experiences
and preferences for day-case anaesthesia .... 199
Appendix 17 Calculating variable costs .... 211
Appendix 18 Determining the quantity
of the volatile anaesthetic agents used ........ 215
Appendix 19 Calculating semi-fixed
costs ................................................................ 223
Appendix 20 NHS staff unit costs .............. 227
Appendix 21 Calculating fixed costs .......... 229
Appendix 22 Quality control procedures .. 231
Appendix 23 Reasons for refusing to
participate in and for withdrawal from
the empirical study ........................................ 233
Appendix 24 Profile of the adult trial........ 235
Appendix 25 Surgical procedure coding
and summarised groups ................................ 237
Appendix 26 Analysis of confounding
factors for PONV in the adult study ............ 241
Appendix 27 Adverse events in the
adult study ...................................................... 247
Appendix 28 Profile of the paediatric
trial.................................................................. 249
Appendix 29 Analysis of confounding
factors for PONV in the paediatric study .... 251
Appendix 30 Adverse events in the
paediatric study .............................................. 253
Health Technology Assessment reports
published to date ........................................ 255
Health Technology Assessment
Programme .................................................. 261